SHANK3 and Phelan-McDermid syndrome: The metabolic findings provide in vitro validation of the hypothesis that abnormal genome-wide DNA methylation and large 22q13 deletions in PHMDS lead to a larger number of disrupted pathways and more severe clinical phenotypes than in cases with small deletions or SHANK3 variants and suggest the existence of distinguishable subtypes of PHMDS.